Frank Womble*, Kathleen McCabe and Imran Naqvi
Department of Internal Medicine, The Jewish Hospital, Bon Secours Mercy Health, Cincinnati, OH, USA
*Corresponding Author:Frank Womble, Department of Internal Medicine, The Jewish Hospital, Bon Secours Mercy Health, Cincinnati, OH, USA.
Received: January 29, 2020; Published: February 11, 2020
As of January 2020, over 2600 hospitalized cases of e-cigarette, or vaping, product use-associated lung injury (EVALI) have been reported by the US Centers for Disease Control and Prevention. EVALI is a serious public health concern prompting regulatory intervention by the Food and Drug Administration. Published cases have certain common features including neutrophil-predominant leukocytosis and elevated inflammatory markers. Severe cases may require intubation and mechanical ventilation. Hospitalized patients often improve with steroids although regimens published in the literature are highly variable. We report an unusually severe case of EVALI with abnormally elevated inflammatory markers, unusually severe transaminitis and lymphopenia that was nevertheless successfully managed with a relatively conservative regimen of glucocorticoids.
Keywords: EVALI; Lung Injury; Vaping; Vaping Injury; VAPI
Citation: Frank Womble., et al. “Vaping Associated Lung Injury – An Unusually Severe Case Rapidly Resolved with a Conservative Steroid Regimen”. Acta Scientific Clinical Case Reports 1.2 (2020): 12-13.
Copyright: © 2020 Frank Womble., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.